Status:
COMPLETED
Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients
Lead Sponsor:
Istituto Clinico Humanitas
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Aim of the study is to assess the impact on response to Herceptin-based therapy in patients with advanced breast cancer. Tumor specimens from primary breast cancer will be analized for several biologi...
Eligibility Criteria
Inclusion
- Hystological diagnosis of breast cancer
- Availability of tumor tissue
- Availability to assess the response to Trastuzumab according to RECIST criteria
- Availability of clinical data
Exclusion
- Unavailability of tumor tissue
- Impossibility to assess the response to Trastuzumab according to RECIST criteria
Key Trial Info
Start Date :
October 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00740532
Start Date
October 1 2007
End Date
August 1 2010
Last Update
September 2 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Clinico Humanitas
Rozzano, Milan, Italy, 20089